Skip to main content
Videos

Femtech in the Spotlight — An Interview with Wolfgang Hackl — Founder and CEO of OncoGenomX

July 11, 2022

Eva von Mühlenen (Advisor, Geneva) and Josefine Sommer (Senior Managing Associate, Brussels) interviewed Wolfgang Hackl, founder of OncoGenomX, a Femtech startup that guides doctors in the treatment of breast cancer — about regulation, research and development (R&D), and the vast potential of artificial intelligence in the field of health technology for women.

 

Contacts

von Mühlenen, Eva
Senior Advisor
Sommer, Josefine
合伙人律师

Related Resources

Related Blogs

Capabilities

Related Pages

Suggested News & Insights

U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 12, 2025
GoodLifeSci
Sidley Represents Immunovant in US$550 Million OfferingDecember 12, 2025
公告
BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025
Government Strategies Update
Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025
荣誉
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025
Global Life Sciences Update
What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025
GoodLifeSci